In this context, the present study aims to evaluate the prognostic value of CSF biomarkers (Aβ42, tTau, pTau) and emerging biomarkers, particularly plasma NfL, in predicting disease progression rate in patients with AD. Here, NEFL is linked to Alzheimer disease.